How untreated menopause drives claim frequency, severity, and premium — and what employers, brokers, and carriers can do about it.
Menopause is the most significant unpriced risk sitting on the workers’ compensation ledger today. It doesn’t appear in loss runs. It doesn’t factor into experience modifiers. It doesn’t show up in a single occupation class. And it is quietly moving frequency and severity across the five categories that dominate every carrier’s book.
Roughly one in four U.S. workers is currently navigating perimenopause or menopause — about 15 million women ages 45–64 in the active labor force. Three out of four report clinically significant symptoms. Roughly a third have symptoms severe enough to impair function. Which means 10 to 12 million symptomatic women are at work on any given day — a population three times larger than the entire U.S. construction workforce, and one whose physiology is quietly degrading the body’s defenses against exactly the injuries WC carriers price.
What none of those figures captures is the downstream workers’ compensation exposure. Every one of the symptom clusters driving the RAND productivity loss — joint pain, poor sleep, brain fog, fatigue, mood dysregulation — maps directly onto a known WC claim driver. The $1.8B figure is the floor, not the ceiling.
Menopause is a physiological state that simultaneously degrades the body’s defenses against the top five causes of workers’ comp claims. Treating it is a workers’ comp intervention, not a benefits intervention.
The Five WC Claim Categories Menopause Quietly Drives
Liberty Mutual’s Workplace Safety Index consistently identifies the same five categories as the largest drivers of serious workplace injury: overexertion, falls on the same level, falls to a lower level, repetitive motion and cumulative trauma, and struck-by/against events. Behind each is a physiological chain that estrogen loss materially weakens.
1. Musculoskeletal Strains and Sprains — roughly 24% of all serious workplace injuries and $13B+ in annual direct U.S. costs. The Musculoskeletal Syndrome of Menopause — arthralgia, tendinopathy, loss of lean muscle, accelerated joint space narrowing — is driven by estrogen withdrawal. Estrogen receptors sit in tendon, ligament, and articular cartilage. Its loss reduces collagen synthesis, tendon stiffness, and tensile strength. Rotator cuff tears, frozen shoulder, and lateral epicondylitis all show up more often in symptomatic menopausal women than in matched asymptomatic peers.
2. Slips, Trips, and Falls — 27% of serious nonfatal injuries and over $17B in annual direct costs. Women can lose up to 20% of bone density within 5–7 years of their final period, moving a previously normal cohort into osteopenia and osteoporosis fast. Estrogen decline also degrades proprioception, vestibular function, and reaction time. Nighttime hot flashes disrupt sleep architecture and produce daytime sleepiness with documented effects on postural control.
3. Cumulative Trauma Disorders — carpal tunnel syndrome (CTS), DeQuervain’s, trigger finger, lateral epicondylitis. CTS prevalence in women ages 45–54 is about three times that of men in the same age band, and the peri- and post-menopausal period is a clinically recognized risk factor. Hormonally-driven fluid retention, tendon sheath inflammation, and reduced nerve conduction velocity all contribute.
4. Fatigue- and Cognition-Related Incidents — 40–60% of menopausal women report clinically significant sleep disturbance; 60–70% report subjective cognitive symptoms including impaired working memory and slowed processing. A large Swiss occupational cohort found workers with sleep problems had 1.6–1.8x higher occupational injury risk. These deficits typically resolve with treatment or with completion of the transition.
5. Stress, Mental Health, and Cumulative Psychological Claims — menopause is associated with a 2–4x increase in risk of major depressive episodes during the transition. Mental health and stress claims are among the fastest-growing categories in U.S. workers’ comp. Even where they’re not directly compensable, depression and anxiety are well-established predictors of delayed return-to-work across virtually every injury type.
Why the Exposure Is Accelerating
Three demographic trends are converging to make this a priority issue for the 2026–2030 renewal cycle:
- The aging of the female workforce. Women ages 55–64 are the fastest-growing segment of the U.S. labor force, at historically high participation rates.
- Delayed retirement. Financial pressure and longevity are keeping women in the workforce 5–10 years longer than a generation ago, extending the symptomatic window deep into the claims-relevant period.
- Increasing recognition and reporting. The 2024 White House Women’s Health Research Initiative and analogous NIH funding are producing more clinical documentation of menopause symptoms than at any prior point — creating the evidentiary base for both legitimate WC claims and discrimination claims.
In plain terms: the baseline claim frequency for symptomatic menopausal employees is already large, and it is structurally increasing. Carriers and employers who don’t adjust will see loss development that outruns their rate plans.
Menopause Is a Modifiable Risk Factor
The most consequential finding in the modern menopause literature is that the dominant symptom clusters are treatable. Hormone therapy, initiated in women under 60 or within 10 years of menopause onset, is the most effective treatment for vasomotor and genitourinary symptoms, with a favorable risk-benefit profile confirmed by the 2022 Menopause Society Position Statement and Manson et al.’s 18-year WHI follow-up in JAMA.
From a risk-management standpoint, this reframes menopause from an immutable demographic fact into a modifiable risk factor — analogous to poorly-controlled diabetes, untreated sleep apnea, or uncorrected vision. Every one of those is an established driver of WC frequency and severity, and every one of them is something carriers and employers already intervene on.
The problem is undertreatment. Faubion et al. estimate that fewer than 20% of symptomatic women are currently receiving appropriate treatment. Every untreated woman in a WC-relevant role is a preventable-frequency event waiting to happen. Treatment improves sleep, cognition, mood, joint pain, bone density, and muscle mass — each an independently validated modifier of the five claim categories above.
The Legal Environment Is Converging
The U.K., working five to ten years ahead of the U.S. on this issue, offers the clearest view of where the litigation arc is heading.
United Kingdom: The Leading Indicator
Rooney v Leicester City Council (2022). The Employment Appeal Tribunal held that menopause symptoms can amount to a “disability” under the Equality Act 2010, triggering the duty to make reasonable adjustments.
Lynskey v Direct Line Insurance Services (2023). An employment tribunal awarded a senior sales consultant more than £64,000 in damages after finding her employer had discriminated against her on grounds of disability (menopause) and failed to make reasonable adjustments. Widely reported as a turning point.
United States: Moving Fast
Rhode Island HB 6161 (effective 2025). First state to explicitly require reasonable workplace accommodations for menopause-related conditions.
Philadelphia Bill No. 250849 (2025). First major U.S. city to add menopause and menstruation to its Fair Practices Ordinance.
Pending in CA, NY, NJ, MA, IL, WA, and OR. Plus the ADAAA framework, which is already available in every jurisdiction today.
Here’s the compounding dynamic carriers should note: the same symptom that produced a discrimination claim (say, untreated hot flashes causing a fall) also produced the underlying WC claim. Employers who have implemented a certified program can demonstrate good-faith compliance across both WC and ADA/Title VII domains simultaneously. Employers who haven’t are exposed on both flanks at once.
What the Intervention Looks Like
TeltraCare operationalizes this insight for employers through a two-part program:
Menopause-Ready Workplace Certification
An 8-pillar program aligned with RI HB 6161, Philadelphia Bill 250849, EEOC ADAAA guidance, and UK precedent. Covers workplace adjustments, education, health support, anti-discrimination policy, accommodation process, communication, monitoring, and audit-ready documentation — the last of which is the single most important element in defending any subsequent WC, ADA, or Title VII claim.
Off-Plan Clinical Care
HIPAA-compliant telehealth connecting employees directly to menopause-trained clinicians, with integrated pharmacy fulfillment for HT and adjunctive therapies. Direct-to-consumer cash pricing means no clinical utilization flows through the group health plan — no new claims-ledger liability, no stop-loss surprises. Materially different from the GLP-1 dynamic that has produced plan-spend volatility for many employers.
The ROI Math
A representative employer of 3,000 (50% female, ~580 women ages 45–64) is looking at roughly 440 symptomatic women and approximately $4.7M in annual productivity and medical exposure before WC is even added. Based on the mechanistic chain across the five claim categories, a reasonable planning estimate is that 8–15% of WC loss development in this cohort is menopause-modifiable.
Conservatively, even a 10–20% reduction in claim frequency in the affected cohort within 12–18 months produces material experience-modifier improvement at renewal. The cohort is large enough — roughly a fifth of total headcount — and the underlying frequency high enough that even modest per-employee effects compound into meaningful premium impact.
Where to Start
The evidence base is complete. The legal exposure is already real. The intervention already exists. Every quarter of delay is a quarter of continued claim development, continued talent loss, and continued regulatory exposure.
For WC Carriers
Begin scoring employer menopause-readiness as a factor in underwriting and loss control. Recognize TeltraCare Certification as a credible risk-mitigation signal. Engage us for book-level analysis of your female 45–64 exposure.
For Benefits & HR Brokers
Bring TeltraCare into the renewal conversation alongside primary medical, pharmacy, and disability. The 8-Pillar Certification is a differentiated service no other vendor in your portfolio offers.
For Employers
Implement now. The financial and legal exposure is already accumulating; the intervention has an evidence base; and the off-plan model means you can move without triggering plan-side complexity.
Turn Menopause Into a Priced, Managed, Modifiable Risk
The employers, brokers, and carriers who get out in front of this won’t be the ones with the biggest budgets. They’ll be the ones who name it first, measure it honestly, and put the right intervention in the workforce before the next renewal cycle prices the exposure in for them.
TeltraCare provides the workplace certification, off-plan clinical care, education, and documentation infrastructure to make menopause a managed line item on your risk ledger — not an invisible one.
Or contact us directly at info@teltracare.com
Sources cited above include: RAND Corporation (2025), Mayo Clinic Proceedings (Faubion et al., 2023), Milliman/Gennev (2023), The Menopause Society 2022 Position Statement, Manson et al. (2017) WHI follow-up in JAMA, Wright et al. (2024) on the Musculoskeletal Syndrome of Menopause, Chidi-Ogbolu & Baar (2019), Uehli et al. (2014), Maki & Weber (2021), Liberty Mutual Workplace Safety Index (2024), BLS/NIOSH, Rooney v Leicester City Council [2022] EAT 23, Lynskey v Direct Line Insurance Services [2023], Rhode Island HB 6161, Philadelphia Bill No. 250849, ADAAA (2008), EEOC guidance, and the 2024 White House Women’s Health Research Initiative.